US · Healthcare · Biotechnology
EPS came in at -0.78 against a street estimate of -0.68 — a miss of 14.7%.
Analysts rate MBX Biosciences, Inc. Common Stock a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $88.36.
| Fund | Stake |
|---|---|
| Frazier Life Sciences Management, L.P. | 13.81% |
| Wellington Management Company LLP | 10.34% |
| Orbimed Advisors LLC | 7.55% |
| NEA Management Company, LLC | 7.51% |
| BlackRock Inc | 6.11% |
| FMR Inc | 6.10% |
| Paradigm Biocapital Advisors LP | 5.21% |
| NVP Associates LLC | 4.44% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q3 2026 MBX BIOSCIENCES, INC. – 8-K SUMMARY HEADLINE NUMBERS • Company: MBX Biosciences, Inc. (Nasdaq: MBX) • Announcement Date: August 27, 2026 • Key Event | 2026-08-27 |
| Quarterly report · Q2 2026 MBX BIOSCIENCES, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash & Marketable Securities: $418.6 million as of June 30, 2026 (Cash: $54.1M; Secu | 2026-08-06 |
| Results announced · Q3 2026 MBX BIOSCIENCES Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash and investments: $418.6 million as of June 30, 2026 • Expected cash runway | 2026-08-06 |
| Board / officer change · Q3 2026 MBX BIOSCIENCES, INC. – 8-K SUMMARY HEADLINE NUMBERS • CEO Departure & Replacement: Kent P. Hawryluk steps down as CEO and Board member effective Ju | 2026-07-13 |
| Reg FD disclosure · Q2 2026 MBX BIOSCIENCES, INC. — 8-K FILING SUMMARY Report Date: June 12, 2026 --- HEADLINE NUMBERS • Primary endpoint (12-week Phase 2 trial): 63% of canvu | 2026-06-12 |
| Quarterly report · Q1 2026 MBX BIOSCIENCES, INC. – Q1 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Cash & marketable securities: $440.0 million as of March 31, 2026 (down from $3 | 2026-05-07 |
| Proxy statement · Q2 2026 MBX BIOSCIENCES, INC. – 2026 PROXY STATEMENT SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Election of Two Class II Directors - Vote | 2026-04-22 |
| Annual report FY2025 MBX BIOSCIENCES, INC. — 10-K SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Public market capitalization as of June 30, 2025: $237,327,692 • S | 2026-03-12 |
Readable in the app.
| Announcement | Date |
|---|---|
| 2026 outlook and business update; clinical trial data anticipated through 2026 MBX Biosciences announced a strong 2026 outlook with multiple clinical catalysts. The company's lead program, once-weekly canvuparatide for hypoparathyroidism, successfully met its Phase 2 p | 2026-01-12 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for MBX Biosciences, Inc. Common Stock — free to start.
Google PlayApp StoreData updated 2026-09-18.